

May 15, 2023

Menicon Co., Ltd.

President and COO: Koji Kawaura

Securities Code: 7780

TSE Prime Market, NSE Premier Market

Contact:

Motonari Watanabe

Senior Executive Officer,

Corporate Management, CFO

Phone: +81-52-935-1646

**Announcement regarding Orthokeratology Lens “Menicon Z Night”  
is Launched in China**

Menicon Co., Ltd. (“the Company”) announced on November 14, 2022 in "Announcement of Approval of “Menicon Z Night” Orthokeratology Contact Lenses in China" that it has obtained approval for the product as a medical device (orthokeratology contact lens) from the National Medical Products Administration (NMPA) of China. The Company announces that the product will be launched in China in May 2023.

For details, please refer to the followings.

End

May 15, 2023

## Orthokeratology Lens “Menicon Z Night” Is Launched in China

Menicon Co., Ltd. (head office: 3-21-19 Aoi, Naka-ku, Nagoya, Japan; President and COO: Koji Kawaura) announces that the orthokeratology lens “Menicon Z Night” will be launched in China in May 2023.

Orthokeratology lenses, hard contact lenses with a specially shaped inner surface, improve myopia by flattening the shape of the cornea. Unlike glasses or regular contact lenses, these contact lenses are worn during sleep, which allows users to lead a comfortable life with good naked eyesight during the day. This technology is suitable when the use of glasses and contact lenses is inconvenient such as when playing sports or doing activities outdoors. Since these lenses correct eyesight without surgery, their use is increasing worldwide.<sup>1)</sup>

The use of orthokeratology lenses reportedly inhibits the progression of myopia.<sup>2)</sup> Accordingly, orthokeratology lenses tend to be frequently prescribed to school-age children in China, and the market for these lenses is expected to approximately triple from 2020 to 2030.<sup>3)</sup>

Menicon Z Night is a product of Menicon B.V., a subsidiary of Menicon Group in the Netherlands. The product is very popular with its users and prescribing physicians in Europe, Southeast Asia, and Australia because of its highly oxygen-permeable Menicon Z materials suitable for orthokeratology lenses worn at bedtime and software that supports the selection of lens specifications based on corneal shape data.

In China, the product will be marketed through Itabashi Medical (Dalian) Co., Ltd., a local subsidiary of Menicon Group, as of May 2023. Menicon Group has already marketed “α Ortho-K” (manufactured by Alpha Corporation of Menicon Group) in the Chinese market, where it is very popular. By adding Menicon Z Night to the lineup, we aim to increase the spread of orthokeratology lenses.

Today, we also announce the launch of ROSE K<sup>®</sup> in China. Menicon will focus on the development and sales not only of regular contact lenses and lens care products but also of specialty lenses. We will contribute broadly to society by continuously providing high value-added products and services for users.

- 1) Contact Lens Spectrum” INTERNATIONAL CONTACT LENS PRESCRIBING IN 2022”
- 2) P Cho et al., Retardation of Myopia in Orthokeratology (ROMIO) Study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci., 2012 53:7077–7085.
- 3) Frost & Sullivan Custom Research (2020)